about
MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesisIdentification and expansion of human colon-cancer-initiating cellsIdentification and expansion of the tumorigenic lung cancer stem cell populationThe miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activitiesA small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cellsEGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potentialPrevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor.Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivoTumour vascularization via endothelial differentiation of glioblastoma stem-like cells.Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancerHuman haemato-endothelial precursors: cord blood CD34+ cells produce haemogenic endotheliummiR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors.Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection.Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.Lamina Propria CD4+LAP+ Regulatory T Cells Are Increased in Active Ulcerative Colitis but Show Increased IL-17 Expression and Reduced Suppressor Activity.Cripto is essential to capture mouse epiblast stem cell and human embryonic stem cell pluripotency.IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.Antitumor effect of miR-197 targeting in p53 wild-type lung cancer.New models for cancer research: human cancer stem cell xenografts.1H NMR detects different metabolic profiles in glioblastoma stem-like cells.Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma.Generation, Quantification, and Tracing of Metabolically Labeled Fluorescent Exosomes.A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression.Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer.Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells.Caveolin-1 tumor-promoting role in human melanomaHigh sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide.Isolation and characterization of CD146+ multipotent mesenchymal stromal cells.A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
P50
Q24649761-1B9E63C3-EB06-4A25-95DA-A5DE962B4CD2Q27860627-201F2A9B-7F7D-4A28-B59D-EE3E6712DD3AQ28259332-7E07A21C-F581-4FB3-83C7-CA22B27B275CQ28297958-250A7E81-0523-42E8-A3BE-5702518CCB0BQ28482952-60E56335-C5AD-42B9-97FB-DF9F44A8372EQ28484249-BBB66C0C-518C-4C47-9C7E-767E6102CBF0Q33396868-57AE71E8-4F08-4111-AEE1-672989E452DAQ33720256-6D928571-E08E-4F3F-AF17-87F00EF3FA3EQ34151513-74E16DB7-B97E-48E0-B1FB-EA6107BA63FDQ34486401-8FCBD3F7-F0E7-4350-A4FF-B35909B2D789Q34506724-4594391C-9BE5-4103-A696-C4572A354561Q34599550-CBDF1E6A-E4FC-4BBB-8024-793FA5C02C73Q34865185-15CD6BA8-EEAA-41D1-BEA4-5E17693478DBQ35861190-6528C43D-319C-4C7D-8001-C651C042F826Q35876285-C5025D56-9F0D-4141-890F-D4D998C888B9Q36048547-B537F2A3-26BA-4971-957E-41FD845265A9Q36545707-9082BD08-A4EB-471F-ADE7-14F5017DB12EQ36560256-3D0D9C1A-8E39-4EBB-91A0-5A5142E205C8Q37118477-714736B6-D6CA-4A84-8AB2-9C4C592808D0Q37260904-752E0893-CC7B-47C7-904D-B17313B51967Q37295663-18F4DB82-CC25-40C5-88AE-62BC1C73A42DQ37418121-4748BB62-63A2-41DE-9C44-BFA1793FB35AQ37689450-4A5F5539-3F54-46BF-9558-81A2C106C885Q37766356-41006F85-3CB9-4342-A361-B6F0366494DBQ38311800-AEF2E3EA-41A1-4208-B61E-1450C4C07A40Q38731608-A22ED653-BB5A-4FFA-849D-51F2625039FEQ38763689-05519170-2858-4537-B3F1-F184F09AE2E9Q38935921-18EECC26-8CCB-4A3B-A202-3948860CFCC2Q39023457-BD96E6F7-15D7-46C6-A075-06F7C9C1FD10Q39041934-D714F88D-A682-4F09-AA6C-04EDB4ABE6BEQ39128618-E90158BA-E27A-4043-8E21-8B0416520A13Q39249155-C3FEB62C-0890-4B8E-A7CE-E1A1897E9B0EQ39321299-877E8AF6-CBF2-447B-A624-6459A36D3BFDQ39344938-D9B1E56F-D36F-4BE3-BB8F-BB22949BF109Q39550421-3523B1A3-3A37-4A36-9EF0-2E16ECC40072Q39690053-D7C3DA75-C403-499A-9726-2F79CF02B953Q39838942-2FA7F09F-0F3D-4481-9313-34D81A14BE9AQ39861298-160A2C01-D93C-4EF9-BA03-7234D4E0CC86Q39978569-1DD5266E-7387-4BC8-AA71-7863268A2D13Q40172413-0BCD12EA-D5EC-4EB1-862A-F679FFD86E57
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mauro Biffoni
@ast
Mauro Biffoni
@en
Mauro Biffoni
@es
Mauro Biffoni
@nl
Mauro Biffoni
@sl
type
label
Mauro Biffoni
@ast
Mauro Biffoni
@en
Mauro Biffoni
@es
Mauro Biffoni
@nl
Mauro Biffoni
@sl
prefLabel
Mauro Biffoni
@ast
Mauro Biffoni
@en
Mauro Biffoni
@es
Mauro Biffoni
@nl
Mauro Biffoni
@sl
P1053
J-8318-2016
P106
P21
P31
P3829
P496
0000-0002-1304-9060